151 related articles for article (PubMed ID: 20976627)
1. Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma.
Savir-Baruch B; Schuster DM; Jarkas N; Master VA; Nieh PT; Halkar RK; Nye JA; Lewis MM; Crowe RJ; Voll RJ; Camp VM; Bellamy LM; Roberts DL; Goodman MM
Mol Imaging Biol; 2011 Dec; 13(6):1272-7. PubMed ID: 20976627
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.
Amzat R; Taleghani P; Miller DL; Beitler JJ; Bellamy LM; Nye JA; Yu W; Savir-Baruch B; Osunkoya AO; Chen Z; Auffermann WF; Goodman MM; Schuster DM
Mol Imaging Biol; 2013 Oct; 15(5):633-43. PubMed ID: 23595643
[TBL] [Abstract][Full Text] [Related]
5. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
[TBL] [Abstract][Full Text] [Related]
6. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.
Schuster DM; Taleghani PA; Nieh PT; Master VA; Amzat R; Savir-Baruch B; Halkar RK; Fox T; Osunkoya AO; Moreno CS; Nye JA; Yu W; Fei B; Wang Z; Chen Z; Goodman MM
Am J Nucl Med Mol Imaging; 2013; 3(1):85-96. PubMed ID: 23342303
[TBL] [Abstract][Full Text] [Related]
7. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and human dosimetry of enantiomer-1 of the synthetic leucine analog anti-1-amino-2-fluorocyclopentyl-1-carboxylic acid.
Nye JA; Jarkas N; Schuster DM; Savir-Baruch B; Voll RJ; Camp VM; Goodman MM
Nucl Med Biol; 2011 Oct; 38(7):1035-41. PubMed ID: 21741251
[TBL] [Abstract][Full Text] [Related]
9. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
[TBL] [Abstract][Full Text] [Related]
10. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
Ren J; Yuan L; Wen G; Yang J
Acta Radiol; 2016 Apr; 57(4):487-93. PubMed ID: 25907118
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis.
Odewole OA; Oyenuga OA; Tade F; Savir-Baruch B; Nieh PT; Master V; Chen Z; Wang X; Jani AB; Bellamy LM; Halkar RK; Goodman MM; Schuster DM
Mol Imaging Biol; 2015 Apr; 17(2):277-83. PubMed ID: 25281411
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.
Nanni C; Schiavina R; Boschi S; Ambrosini V; Pettinato C; Brunocilla E; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S11-7. PubMed ID: 23591953
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
14. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
15. Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.
Kairemo K; Rasulova N; Partanen K; Joensuu T
Biomed Res Int; 2014; 2014():305182. PubMed ID: 24991547
[TBL] [Abstract][Full Text] [Related]
16. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
17. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
18. Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer.
Inoue Y; Asano Y; Satoh T; Tabata K; Kikuchi K; Woodhams R; Baba S; Hayakawa K
Asia Ocean J Nucl Med Biol; 2014; 2(2):87-94. PubMed ID: 27408864
[TBL] [Abstract][Full Text] [Related]
19. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
[TBL] [Abstract][Full Text] [Related]
20. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
Steiner Ch; Vees H; Zaidi H; Wissmeyer M; Berrebi O; Kossovsky MP; Khan HG; Miralbell R; Ratib O; Buchegger F
Nuklearmedizin; 2009; 48(1):1-9; quiz N2-3. PubMed ID: 19212605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
